Maria Josep Cabañas Poy

Maria Josep Cabañas Poy

Auto-generated profile, based on publicly available information

Maria Josep Cabañas Poy

Department of Hospital Pharmacy, Hospital Universitario Vall d’Hebron, 08035 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2025 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
CPCarlos Javier Parramon-Teixido
Carlos Javier Parramon-Teixido
LRLucía Rodríguez-Pombo
Lucía Rodríguez-Pombo
ABAbdul W Basit
Abdul W Basit
AWAnna Worsley
Anna Worsley
CCCarme Cañete-Ramírez
Carme Cañete-Ramírez
AGAlvaro Goyanes
Alvaro Goyanes
The integration of 3D printing (3DP) technologies into personalized medicine manufacture at the point-of-care is garnering significant interest due to its potential to create tailored drug products with precise dosages and other unique attributes. Both preclinical and clinical studies have demonstrated promising outcomes, including pharmacokinetic bioequivalence, improved patient acceptability, enhanced adherence, and the ability to produce consistent, reproducible dosage forms with accurate drug distribution. Some compounding pharmacies around the world are already incorporating 3DP into standard practice for simpler therapeutic treatments. However, further clinical evaluation is required for more complex treatments, such as multi-drug polypills. Conducting clinical trials involving 3DP technologies presents several challenges, including navigating evolving regulatory frameworks, addressing ethical and legal concerns, and complying with new point-of-care manufacturing guidelines. Although regulatory agencies are beginning to adapt their policies to accommodate 3DP, the absence of a comprehensive framework still creates uncertainty for pharmacists and healthcare providers. This article explores the planning and execution of clinical trials involving 3D printed medicines, with a focus on regulatory barriers, patient recruitment, compliance, and the integration of specialized equipment and expertise. It also discusses the implementation of 3DP for personalized drug manufacturing within hospital settings and offers guidance for obtaining clinical trial approval from the Spanish Agency for Medicine and Health Products (AEMPS). By providing these insights and recommendations, this article aims to support international harmonization and facilitate the adoption of 3DP technologies in clinical trials globally.

1 January 2005 in Farmacia Hospitalaria
Verified
Journal Article
Open access
RMR. López Martínez
R. López Martínez
MPM.J. Cabañas Poy
M.J. Cabañas Poy
MAM. Oliveras Arenas
M. Oliveras Arenas
SBSusana Clemente Bautista
Susana Clemente Bautista
Many drugs prescribed in pediatric units do not meet the conditions of use defined in their corresponding prescription information sheets, or their use has not been approved by the Spanish Health Authorities. The lack of clinical trials in children, and of adequate dosage forms, reduces drug safety, assuming both the physician and the pharmacist the responsibility for the drug use. To assess drug prescription status within a neonatal intensive care unit in a third-level hospital. A 3-months prospective study was performed, and information was collected from all admitted children along four time periods. Sixty-one complete therapies were evaluated, with a total of 236 drugs prescribed. Fifty percent were off-label, 13% were unlicensed, and 37% were correctly used. These figures resemble those from, similar studies carried out in other European hospitals. This is therefore a common practice resulting from the need to treat. Health authorities should encourage clinical trials so that drug therapies for children become evidence-based.

1 January 2007 in Farmacia Hospitalaria
Verified
Journal Article
Open access
APA. Fernández Polo
A. Fernández Polo
MPM.J. Cabañas Poy
M.J. Cabañas Poy
SBS. Clemente Bautista
S. Clemente Bautista
MAM. Oliveras Arenas
M. Oliveras Arenas
FSFelix Castillo Salinas
Felix Castillo Salinas
EAE. Hidalgo Albert
E. Hidalgo Albert
Oral administration of hypertonic solutions can contribute to intestinal damage in the initial stages of neonatal necrotizing enterocolitis. The purpose of this study is to determine the osmolality of oral liquid dosage forms used in a division of neonatology and to establish some recommendations for their dilution. The osmolality of 26 oral liquid dosage forms has been measured using the freezing-point depression method. Oral liquid dosage forms used in the division of neonatology present an osmolality greater than 350 mOsm/kg H2O. 19.2% of all the analysed forms presented an osmolality lower than 1500 mOsm/kg H2O, 80.7% were over that figure, while 23% presented an extremely high osmolality (> 5,000 mOsm/kg H2O). Knowledge of osmolality of oral liquid dosage forms in the division of neonatology enables the risk of intestinal aggression caused by enteral administration of the medication to be assessed.


22 June 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
MPMa José Cabañas Poy
Ma José Cabañas Poy
JRJosé Bruno Montoro Ronsano
José Bruno Montoro Ronsano
FSFélix Castillo Salinas
Félix Castillo Salinas
NBNieves Martín Begué
Nieves Martín Begué
SBSusana Clemente Bautista
Susana Clemente Bautista
MTMa Queralt Gorgas Torner
Ma Queralt Gorgas Torner
To study the association between gestational age (GA) and weight at birth and the development of retinopathy of prematurity (ROP), and in particular the link between postnatal weight gain during th...

10 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SBSusana Clemente Bautista
Susana Clemente Bautista
OSOscar Segarra
Oscar Segarra
NPNúria Padullés-Zamora
Núria Padullés-Zamora
SGSonia Garcia Garcia
Sonia Garcia Garcia
MAMarina Alvarez-Beltran
Marina Alvarez-Beltran
MMMarta Miarons
Marta Miarons
Background: This study evaluated the long-term effectiveness and safety of a multidisciplinary early proactive therapeutic drug monitoring (TDM) program combined with Bayesian forecasting for infliximab (IFX) dose adjustment in a real-world dataset of paediatric patients with inflammatory bowel disease (IBD). Methods: A descriptive, ambispective, single-centre study of paediatric patients with IBD who underwent IFX serum concentration measurements between September 2015 and September 2023. The patients received reactive TDM before September 2019 (n = 17) and proactive TDM thereafter (n = 21). We analysed for clinical, biological, and endoscopic remission; treatment failure; hospitalisations; emergency visits; and adverse drug reactions. The IFX doses were adjusted to maintain trough concentrations ≥ 5 µg/mL, with specific targets for proactive TDM. Results: Of the 38 patients, 21 had Crohn’s disease (CD), 16 ulcerative colitis (UC), and 1 undetermined IBD. The mean (standard deviation) IFX trough concentrations were 6.83 (5.66) µg/mL (reactive) and 12.38 (9.24) µg/mL (proactive) (p = 0.08). No statistically significant differences between groups were found in remission rates or treatment failure. The proactive group had fewer hospitalisations (14.29% vs. 23.53%; p = 0.47) and shorter median hospitalisation days (6 vs. 19; p = 0.50), although the difference was not statistically significant. The number of patients with adverse reactions (infusion related reactions and infections) was higher in the proactive group (38.10% vs. 23.53%; p = 0.34) but the difference was not significantly different. Conclusions: Proactive TDM showed no significant differences in treatment outcomes compared to reactive TDM. However, the results in both the reactive and proactive TDM groups were not worse than those reported in other studies. Further studies with larger samples are needed to optimize the treatment strategies for pediatric IBD patients.